Results 201 to 210 of about 112,082 (305)

Body Mass Index and All‐Cause, Cancer, and Cardiovascular Mortality in Adults Aged 16–50 Years With and Without Type 2 Diabetes: An Analysis of Primary Care Records in England

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine the association between body mass index (BMI) and risk of all‐cause, cancer, and cardiovascular diseases (CVD) mortality among adults aged 16–50 years with and without type 2 diabetes (T2D). Materials and Methods We conducted a retrospective matched cohort study using primary care records from the Clinical Practice Research ...
Yijing Chen   +6 more
wiley   +1 more source

Management of Proteinuria in Dogs and Cats with Chronic Kidney Disease [PDF]

open access: yes, 2016
Atkins   +46 more
core   +2 more sources

Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Prediabetes and left ventricular hypertrophy (LVH) are common risk factors in adults with hypertension. Whether their coexistence, particularly in the presence of subclinical myocardial injury or stress (malignant LVH), confers a heightened stroke risk is unknown.
Arnaud D. Kaze   +7 more
wiley   +1 more source

Ancestry‐based antihypertensive therapy: Beware of pitfalls

open access: yes
Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Meryam Sugulle, Patji Alnæs‐Katjavivi
wiley   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh   +2 more
wiley   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

open access: yesHepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori   +17 more
wiley   +1 more source

Polytropic Influence of TRIB3 rs2295490 Genetic Polymorphism on Response to Antihypertensive Agents in Patients With Essential Hypertension. [PDF]

open access: yesFront Pharmacol, 2019
Zhou J   +14 more
europepmc   +1 more source

Loss of Posterior Occlusal Support Is Associated With Incident Steatotic Liver Disease in a Nationwide Longitudinal Analysis of the JMDC Claims Database

open access: yesHepatology Research, EarlyView.
ABSTRACT Aim Steatotic liver disease (SLD), including metabolic dysfunction–associated SLD (MASLD) and metabolic dysfunction–associated alcohol‐related liver disease (MetALD), is a growing global health burden. Although impaired mastication is linked to metabolic disorders, its role in SLD remains unclear.
Takashi Miyano   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy